A Systematic Review of Physicians’ and Pharmacists’ Perspectives on Generic Drug Use: What are the Global Challenges?

Abstract

Background and ObjectivesGeneric substitution has been introduced in most countries in order to reduce costs and improve access to drugs. However, regulations and the generic drugs available vary between countries. It is the prescriber or dispenser of the drug who is the final decision maker. Nevertheless, physicians’ and pharmacists’ perceptions of generic drug use are not well documented to date. This study presents a systematic review of physicians’ and pharmacists’ perspectives on generic drug use worldwide.MethodsA systematic literature search was performed to retrieve all articles published between 2002 and 2012 regarding physicians’ and/or pharmacists’ experiences with generic drugs and generic substitution.ResultsOf 1322 publications initially identified, 24 were eligible for inclusion. Overall, the studies revealed that physicians and pharmacists were aware of the cost-saving function of generic drugs and their role in improving global access to drugs. Nevertheless, marked differences were observed between countries when studying physicians’ and pharmacists’ perceptions of the available generic drugs. In less mature healthcare systems, large variations regarding, for example, control routines, bioequivalence requirements, and manufacturer standards were reported. A lack of reliable information and mistrust in the efficacy and quality were also mentioned by these participants. In the most developed healthcare systems, the participants trusted the quality of the generic drugs and did not hesitate to offer them to all patients regardless of socioeconomic status. In general, pharmacists seemed to have better knowledge of the concept of bioequivalence and generic drug aspects than physicians.ConclusionsThe present study indicates that physicians and pharmacists are aware of the role of generic drugs in the improvement of global access to drugs. However, there are marked differences regarding how these health professionals view the quality of generic drugs depending on the maturity of their country’s healthcare system. This can be attributed to the fact that developed healthcare systems have more reliable public control routines for drugs in general as well as better bioequivalence requirements concerning generics in particular.

Perceptions and utilization of generic medicines in Guatemala: a mixed-methods study with physicians and pharmacy staff

“…One review examining physician perspectives of generic drugs found that doctors in LMICs tend to have less positive views of generics compared to doctors in high-income countries, who had more positive perceptions [49]. Another review of both physician and pharmacist perceptions of generics similarly distinguished between the high trust of generics in mature health systems and the low trust in generic quality, manufacturing, and bioequivalence in less mature health systems [50]. …”

The effect of the implementation of evidence-based drug formulary on antibacterial use in a private hospital at Tanjung Enim, Sumatera Selatan, Indonesia

“…The evidence-based treatment approach for infectious diseases based on the results of current studies is really needed to update the knowledge in antibacterial drug use. [9][10][11][12] Patterson et al reported that 92% antibacterial drug prescribing by general practitioners for otitis media was inappropriate, and based on microbiological analysis, there were no bacteria found. The type of antibacterial prescribed was often incorrect because the prescribing was generally not consistent with the suspected pathogenic bacteria.…”

Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a ‘real-world’ retrospective cohort study

“…32 According to Italian law (Patent Law and the Health Law Regulations in Italy. Decree 95/2012), all pharmacists in Italy are required to offer patients the opportunity to substitute a prescribed non-generic, interchangeable medicinal product with a less expensive generic alternative, unless the prescriber states specifically that the prescription is non-substitutable.…”